This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Craig-Hallum Initiates a Buy Rating on Actuate Therapeutics, Inc. (ACTU)
In a report released today, Albert Lowe from Craig-Hallum initiated coverage with a Buy rating on Actuate Therapeutics, Inc. (ACTU – Research Report) and a price target of $32.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Lowe is an analyst with an average return of -9.5% and a 39.39% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Rezolute, and Lineage Therap.
Currently, the analyst consensus on Actuate Therapeutics, Inc. is a Moderate Buy with an average price target of $20.00.
The company has a one-year high of $11.99 and a one-year low of $5.51. Currently, Actuate Therapeutics, Inc. has an average volume of 54.31K.
Read More on ACTU:
Disclaimer & DisclosureReport an Issue
- Actuate Therapeutics shares highlights from KOL eventon elraglusib data
- Actuate Therapeutics Reports Positive Phase 2 Trial Results
- Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib
- Actuate Therapeutics Elects Directors at Annual Meeting
- Actuate Therapeutics to host KOL event on Phase 2 elraglusib data
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
